FDA Scientific Initiatives Will Not Change After Election, Crawford Predicts
Executive Summary
FDA's scientific initiatives will not be affected by the outcome of the Nov. 2 Presidential elections, Acting Commissioner Lester Crawford said Oct. 10 at an R&D conference sponsored by Phacilitate in Geneva, Switzerland
You may also be interested in...
Pharmacogenomics working group (correction)
GlaxoSmithKline Director-Clinical Pharmacogenetics Mark Watson, MD/PhD, is the chair of the Pharmacogenetics Working Group. "The Pink Sheet" incorrectly reported that Wyeth Senior Director-Regulatory Affairs Ronald Salerno was the chair of the pharmacogenetics working group (1"The Pink Sheet" Oct. 11, 2004, p. 13). Salerno stepped down in July. The working group is not sponsored by the Pharmaceutical Research & Manufacturers of America; it was formed from the pharmacogenetics special interest group of the Drug Information Association in 2000. PhRMA's Genomics Division, which was formed in 2002, is chaired by Millennium Pharmaceuticals Director-Regulatory Strategy & Intelligence Christopher Webster, PhD...
Pharmacogenomics working group (correction)
GlaxoSmithKline Director-Clinical Pharmacogenetics Mark Watson, MD/PhD, is the chair of the Pharmacogenetics Working Group. "The Pink Sheet" incorrectly reported that Wyeth Senior Director-Regulatory Affairs Ronald Salerno was the chair of the pharmacogenetics working group (1"The Pink Sheet" Oct. 11, 2004, p. 13). Salerno stepped down in July. The working group is not sponsored by the Pharmaceutical Research & Manufacturers of America; it was formed from the pharmacogenetics special interest group of the Drug Information Association in 2000. PhRMA's Genomics Division, which was formed in 2002, is chaired by Millennium Pharmaceuticals Director-Regulatory Strategy & Intelligence Christopher Webster, PhD...
FDA Wants To Be “Model” Agency: Preparing For Clinical Trial Simulations
FDA plans to make greater use of mathematical and statistical models to guide drug development and approval decisions, Center for Drug Evaluation & Research Scientific Advisor Donald Stanski said Oct. 5 at a R&D conference sponsored by Phacilitate in Geneva, Switzerland